Neos Therapeutics Inc (NEOS) was Reiterated by RBC Capital Mkts to “Outperform” while Lowering the Price Target of the company shares to $ 29 from a previous price target of $33 . RBC Capital Mkts advised their investors in a research report released on May 17, 2016.
Many Wall Street Analysts have commented on Neos Therapeutics Inc. Neos Therapeutics Inc was Initiated by Wells Fargo to “Outperform” on Feb 19, 2016.
Neos Therapeutics Inc. is a pharmaceutical company develops manufactures and commercializes products for the treatment of attention deficit hyperactivity disorder (ADHD) using its drug delivery technologies. The Companys product candidates are extended-release (XR) medications in orally disintegrating tablets or liquid suspension dosage forms. It manufactures and markets generic Tussionex a hydrocodone polistirex and chlorpheniramine polistirex XR liquid suspension product indicated for the relief of cough and upper respiratory symptoms associated with allergies or colds in adults and children of six years of age and older. Its product candidates include NT-0102 methylphenidate XR orally disintegrating tablet for the treatment of ADHD; NT-0202 amphetamine XR orally disintegrating tablet for the treatment of ADHD and NT-0201 amphetamine XR liquid suspension for the treatment of ADHD. The company is headquartered in Grand Prairie Texas.